Q-linea postpones start of the clinical trials

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), today announced that the clinical trials, in the United States and Europe, for the company's first product ASTar® are expected to begin in the second half of 2020. This is a postponement as the trials previously were expected to start in the first quarter of 2020. The reason is partly that Q-linea during the evaluation of ASTar during the autumn realized that the reliability of a third-party component needs to be improved. In addition, Q-linea have conducted several interviews with physicians in Europe and the US during the summer. With the new timeline, the company plan to investigate the possibility of including Meropenem-Vaborbactam (MER-VAB) into its antibiotic panel to provide a more comprehensive analytical result for patients with resistant bacterial infections.

Q-linea strengthens management team

UPPSALA, Sweden, 3 September, 2019 - Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, today announced Thomas Fritz has been appointed the company’s Chief Commercial Officer and will be part of Q-linea’s management team.  

Q-linea strengthens management team

UPPSALA, Sweden, 12 July, 2019 - Q-linea AB (publ) (Nasdaq Stockholm:QLINEA), a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, today announced MD Tiziana Di Martino has been appointed the company’s Chief Medical Officer and will be part of Q-linea’s management team.

Notice of Annual General Meeting in Q-Linea AB (publ)

The shareholders in Q-linea AB (publ), reg. no. 556729-0217 (the “Company”) are hereby convened to the annual general meeting on Wednesday 22 May 2019, at 4 pm in Konferens Hubben (conference room 3+4) with address Dag Hammarskjölds väg 38, 752 37 Uppsala.

Q-linea’s ASTar – a success on ECCMID

Q-linea AB (publ) (OMX: QLINEA), a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, now presents the final design of ASTar for potential customers at the most important trade fair; the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), this year being held in Amsterdam, 13-16 April.

Q-linea can reach its main market faster than planned

Q-linea AB (publ) (OMX: QLINEA), today announced that the company's first product ASTar® is expected to launch on the company’s main market, the U.S., three to four months than earlier communicated to take advantage of strong market interest and positive feedback from the US Food and Drug Administration, the FDA. The European launch is thus postponed to the same extent.

Stabilization notice and end of the stabilization period

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES

Stabilization notice

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES Carnegie Investment Bank AB (publ) (”Carnegie”) notifies that stabilization measures have been undertaken in Q-linea AB (publ) (”Q-linea” or the “Company”) shares traded on Nasdaq Stockholm.

Trading in Q-linea’s share commences tomorrow on Nasdaq Stockholm

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

Q-linea publishes prospectus for Initial Public Offering on Nasdaq

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

Q-linea intends to list its shares on Nasdaq Stockholm

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

Notice to extraordinary general meeting in Q-linea AB

In Swedish only. Aktieägarna i Q-linea AB (publ), org.nr. 556729-0217 (”Bolaget”), kallas härmed till extra bolagsstämma måndagen den 12 november 2018 kl. 09.30 i Advokatfirman Lindahls lokaler, Vaksalagatan 10, Uppsala.

Q-linea AB acquires Umbrella Science

UPPSALA, Sweden, June 30th, 2018 - Q-linea AB, a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, announced that the company has acquired Umbrella Science AB in an asset deal. The total purchase price is SEK 12.8 million.

Q-linea AB secures SEK 151.5 million in funding

UPPSALA, Sweden, June 18, 2018 - Q-linea AB, a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, announced today that the company secured SEK 151.5 million from existing shareholders and a group of Swedish investors. Lead investors were Investment AB Öresund and the Fourth AP fund.